Document Detail


Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
MedLine Citation:
PMID:  17405748     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure. The loss of CD20 expression in B-cell lymphomas relapsing after rituximab is a well-known phenomenon, but its actual impact in DLBCL is difficult to estimate. This paradigmatic case suggests that CD20-expression reappearance after purging of CD20-positive clones with rituximab might be an underestimated occurrence in B-cell lymphomas. Accordingly, every relapse, whenever possible, should be histologically assessed with diagnostic and immunophenotyping purposes.
Authors:
A J Ferreri; G P Dognini; C Verona; C Patriarca; C Doglioni; M Ponzoni
Related Documents :
2023568 - Primary subconjunctival lymphoma: an unusual presentation of childhood non-hodgkin's ly...
16766838 - Nasal extranodal nk/t-cell lymphoma presenting as a perforating palatal ulcer: a diagno...
16194898 - Translocation of bcl2 and bcl6 to the same immunoglobulin heavy chain locus in a case o...
3699808 - Small noncleaved cell lymphoma: an immunophenotypic study of 18 cases and comparison wi...
20825288 - An unusual case of symptomatic schwannoma on the elbow.
8321018 - Effects of recombinant human hematopoietic growth factors on leukemic blasts from child...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Haematologica     Volume:  92     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-04-04     Completed Date:  2007-12-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  e1-2     Citation Subset:  IM    
Affiliation:
Medical Oncology Unit, Dept. of Oncology, San Raffaele H Scientific Institute, Milan, Italy. andres.ferreri@hsr.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged, 80 and over
Antibodies, Monoclonal / pharmacology,  therapeutic use*
Antigens, CD20 / biosynthesis*,  drug effects,  genetics
Antigens, Neoplasm / biosynthesis*,  drug effects,  genetics
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Epirubicin / administration & dosage
Fatal Outcome
Gene Expression Regulation, Neoplastic*
Humans
Immunologic Factors / pharmacology,  therapeutic use*
Immunophenotyping*
Immunotherapy*
Lymphatic Irradiation
Lymphoma, Large B-Cell, Diffuse / metabolism*,  therapy
Male
Neoplasm Recurrence, Local / metabolism*,  pathology,  therapy
Prednisone / administration & dosage
Stomach Neoplasms / metabolism*,  therapy
Vincristine / administration & dosage
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Antigens, Neoplasm; 0/Immunologic Factors; 0/rituximab; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 56420-45-2/Epirubicin; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
Next Document:  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to a...